| Literature DB >> 36051632 |
Ho Yin Chung1, Jin Xian Huang2, Kam Ho Lee3, Helen Hoi Lun Tsang1, Chak Sing Lau1, Shirley Chiu Wai Chan4.
Abstract
Background: Magnetic resonance imaging (MRI) is important in the management of axial spondyloarthritis (SpA). However, many MRI lesions are not exclusive to axial SpA. Further characterization of these lesions may lead to better clinical decisions. Objective: The objective of this study was to compare the frequency of individual spinal MRI lesions between axial SpA and noninflammatory back pain. The factors associated with individual lesions in participants with axial SpA were also determined. Design: This was a cross-sectional observational study.Entities:
Keywords: magnetic resonance imaging; spondyloarthritis
Year: 2022 PMID: 36051632 PMCID: PMC9425894 DOI: 10.1177/1759720X221119250
Source DB: PubMed Journal: Ther Adv Musculoskelet Dis ISSN: 1759-720X Impact factor: 3.625
Baseline characteristics of participants with axial SpA and noninflammatory back pain.
| Axial SpA ( | Noninflammatory back pain ( | ||
|---|---|---|---|
| Age (years) | 44.9 ± 14.0 | 48.1 ± 15.0 | 0.01 |
| Male gender | 261/447 (58.4%) | 39/122 (32.0%) | <0.001 |
| Chinese ethnicity | 440/447 (98.4%) | 122/122 (100%) | 0.16 |
| Smoking | 112/447 (25.1%) | 19/122 (15.6%) | 0.03 |
| Regular alcohol use | 43/447 (9.6%) | 9/122 (7.4%) | 0.44 |
| Age of back pain onset (years; mean ± SD) | 32.8 ± 13.7 | 40/0 ± 14.8 | <0.001 |
| Duration of back pain (years) (mean ± SD) | 12.1 ± 11.5 | 8.1 ± 9.0 | <0.001 |
| Family history of SpA | 105/447 (23.5%) | 8/122 (6.6%) | <0.001 |
| HLA-B27 positive | 349/426 (81.9%) | 9/102 (8.9%) | <0.001 |
| History of PsO | 62/447 (13.9%) | N/A | N/A |
| History of IBD | 11/447 (2.5%) | N/A | N/A |
| History of dysentery or sexually transmitted disease preceding SpA | 6/438 (1.4%) | N/A | N/A |
| History of uveitis | 154/446 (34.5%) | N/A | N/A |
| Back pain NRS | 5.4 ± 2.5 | 5.6 ± 2.5 | 0.20 |
| BASDAI (mean ± SD) | 4.5 ± 2.1 | N/A | N/A |
| BASFI (mean ± SD) | 2.8 ± 2.4 | N/A | N/A |
| BAS-G (mean ± SD) | 4.8 ± 2.5 | N/A | N/A |
| CRP mg/dl (mean ± SD) | 1.2 ± 3.1 | 0.4 ± 1.6 | <0.001 |
| ESR mm/hr (mean ± SD) | 31.3 ± 25.1 | 29.1 ± 22.3 | 0.41 |
| ASDAS-CRP (mean ± SD) | 1.9 ± 0.9 | N/A | N/A |
| ASDAS-ESR (mean ± SD) | 3.0 ± 1.0 | N/A | N/A |
| Tender joint count (mean ± SD) | 1.6 ± 3.2 | N/A | N/A |
| Swollen joint count (mean ± SD) | 0.5 ± 1.4 | N/A | N/A |
| BASMI (mean ± SD) | 3.4 ± 1.7 | N/A | N/A |
| Radiographic axial SpA | 242/440 (55.0%) | N/A | N/A |
| mSASSS (mean ± SD) | 12.2 ± 18.1 | N/A | N/A |
| mSASSS >2 | 240/397 (60.5%) | N/A | N/A |
| MRI spine inflammation | 217/447 (48.6%) | 38/122 (31.1%) | <0.001 |
| SPARCC MRI spine | 5.3 ± 7.9 | N/A | N/A |
| MRI SI joint inflammation | 134/442 (30.3%) | 3/122 (2.5%) | <0.001 |
| SPARCC MRI SI joint | 3.1 ± 6.0 | N/A | N/A |
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondyloarthritis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BA1S-G, Bath Ankylosing Spondylitis Global score; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; kg, kilogram; MRI, magnetic resonance imaging; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; n, number; N/A, not available; NRS, numerical rating score; PsO, psoriasis; SD, standard deviation; SI, sacroiliac; SpA, spondyloarthritis.
Prevalence of different MRI lesions.
| Participants with axial SpA ( | Participants with noninflammatory back pain ( | ||
|---|---|---|---|
| DVL | 120/447 (26.8%) | 23/122 (18.9%) | 0.07 |
| Modic type 1 lesion | 47/447 (10.5%) | 17/122 (13.9%) | 0.29 |
| DVL without Modic type 1 lesion | 73/447 (16.3%) | 6/122 (4.9%) | <0.01 |
| Cervical DVL | 31/442 (7.0%) | 6/118 (5.1%) | 0.45 |
| Cervical Modic type 1 lesion | 13/442 (2.9%) | 5/118 (4.2%) | 0.48 |
| Thoracic DVL | 68/442 (15.4%) | 2/118 (1.7%) | <0.001 |
| Thoracic Modic type 1 lesion | 13/442 (2.9%) | 0/118 (0.0%) | 0.06 |
| Lumbar DVL | 41/442 (9.3%) | 17/118 (14.4%) | 0.10 |
| Lumbar Modic type 1 lesion | 26/442 (5.9%) | 13/118 (11.0%) | 0.05 |
| Facet joint lesion | 35/447 (7.8%) | 3/122 (2.5%) | 0.04 |
| Cervical facet joint lesion | 3/447 (0.7%) | 0/122 (0.0%) | 0.36 |
| Thoracic facet joint lesion | 21/447 (4.7%) | 1/122 (0.8%) | 0.05 |
| Lumbar facet joint lesion | 20/447 (4.5%) | 2/122 (1.6%) | 0.15 |
| Costovertebral lesion | 50/447 (11.2%) | 1/122 (0.8%) | <0.001 |
| CIL | 205/447 (45.9%) | 28/122 (23.0%) | <0.001 |
| Number of CIL | 2.0 ± 3.4 | 0.5 ± 1.1 | <0.001 |
| Number of cervical CIL | 0.1 ± 0.7 | 0.0 ± 0.3 | 0.02 |
| Number of thoracic CIL | 1.6 ± 3.0 | 0.2 ± 0.9 | <0.001 |
| Number of lumbar CIL | 0.4 ± 0.9 | 0.2 ± 0.7 | 0.02 |
| FCL | 154/447 (34.5%) | 36/122 (29.5%) | 0.31 |
| Number of FCL | 5.0 ± 8.1 | 1.2 ± 2.1 | <0.001 |
| Number of cervical | 0.6 ± 1.8 | 0.2 ± 0.7 | <0.001 |
| Number of thoracic | 2.9 ± 4.9 | 0.3 ± 0.9 | <0.001 |
| Number of lumbar | 1.6 ± 2.8 | 0.6 ± 1.3 | <0.001 |
CIL, corner inflammatory lesion; DVL, discovertebral lesion; FCL, fatty corner lesion; MRI, magnetic resonance imaging; n, number; N/A, not available; SD, standard deviation; SpA, spondyloarthritis; SPARCC, Spondyloarthritis Research Consortium of Canada.
Chances of occurrence of different MRI lesions in axial SpA when compared with noninflammatory back pain by propensity score adjustment.
| OR (95% CI) | ||
|---|---|---|
| DVL ( | 1.59 (0.94, 2.70) | 0.09 |
| Modic Type 1 lesion ( | 0.82 (0.43, 1.55) | 0.54 |
| DVL without Modic type 1 lesion ( | 3.43 (1.41, 8.30) | 0.01 |
| Facet joint lesion ( | 2.56 (0.74, 8.81) | 0.14 |
| Costovertebral lesion ( | 11.89 (1.60, 88.56) | 0.02 |
| Regression coefficient (95% CI) | ||
| Number of CIL ( | 1.19 (0.54, 1.83) | <0.001 |
| Number of cervical CIL ( | 0.08 (–0.06, 0.23) | 0.27 |
| Number of thoracic CIL ( | 1.02 (0.45, 1.58) | <0.001 |
| Number of lumbar CIL ( | 0.10 (–0.09, 0.28) | 0.29 |
| Number of FCL ( | 3.33 (1.78, 4.89) | <0.001 |
| Number of cervical FCL ( | 0.32 (–0.03, 0.67) | 0.07 |
| Number of thoracic FCL ( | 2.28 (1.34, 3.22) | <0.001 |
| Number of lumbar FCL ( | 0.80 (0.27, 1.34) | <0.01 |
Covariates included in the propensity score are as follows: age, male gender, Chinese ethnicity, smoker, regular alcohol use, age of onset of back pain, duration of back pain, and family history of SpA.
CI, confidence interval; CIL, corner inflammatory lesion; DVL, discovertebral lesion; FCL, fatty corner lesion; OR, odds ratio.
Logistic regression analyses of factors associated with DVL without Modic type 1 lesion.
| DVL without Modic type 1 lesion | OR (95% CI) |
| ||
|---|---|---|---|---|
| OR (95% CI) |
| |||
| Age ( | 1.00 (0.98, 1.02) | 0.63 | ||
| Male gender ( | 1.35 (0.80, 2.28) | 0.26 | ||
| Chinese ethnicity (447) | 0.25 (0.06, 1.15) | 0.08 | 0.28 (0.06, 1.34) | 0.11 |
| Smoking ( | 1.47 (0.85, 2.55) | 0.17 | ||
| Regular alcohol use ( | 0.65 (0.25, 1.71) | 0.38 | ||
| Age of back pain onset ( | 0.99 (0.97, 1.01) | 0.42 | ||
| Duration of back pain ( | 1.02 (1.00, 1.04) | 0.13 | ||
| Family history of SpA ( | 0.90 (0.49, 1.64) | 0.73 | ||
| HLA-B27 positivity ( | 1.22 (0.61, 2.45) | 0.58 | ||
| Radiographic axial SpA ( | 2.50 (1.44, 4.34) | 0.001 | 2.46 (1.41, 4.29) | 0.001 |
CI, confident interval; DVL, discovertebral lesion; HLA, human leucocyte antigen; n, number; OR, odds ratio; SpA, spondyloarthritis.
Logistic regression analyses of factors associated with costovertebral lesions.
| Costovertebral lesion | Univariate logistic regressions | Multivariate logistic regressions | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Age ( | 0.99 (0.97, 1.01) | 0.48 | ||
| Male gender ( | 1.77 (0.93, 3.34) | 0.08 | 1.39 (0.71, 2.73) | 0.34 |
| Chinese ethnicity ( | 0.75 (0.09, 6.48) | 0.79 | ||
| Smoking ( | 2.00 (1.08, 3.71) | 0.03 | 1.43 (0.74, 2.76) | 0.29 |
| Regular alcohol use ( | 1.33 (0.53, 3.32) | 0.55 | ||
| Age of back pain onset ( | 1.00 (0.97, 1.02) | 0.67 | ||
| Duration of back pain ( | 0.96 (0.97, 1.02) | 0.67 | ||
| Family history of SpA ( | 1.63 (0.86, 3.09) | 0.14 | ||
| HLA-B27 positivity ( | 1.62 (0.66, 3.96) | 0.29 | ||
| Radiographic axial SpA ( | 4.28 (2.03, 9.05) | <0.001 | 3.86 (1.80, 8.24) | <0.001 |
CI, confident interval; HLA, human leucocyte antigen; n, number; OR, odds ratio; SpA, spondyloarthritis.
Linear regression analyses of factors associated with CIL and FCL.
| Univariate linear regressions | Multivariate linear regressions | |||||
|---|---|---|---|---|---|---|
| Standard coefficient ( | Regression coefficient (95% CI) | Standard coefficient ( | Regression coefficient (95% CI) | |||
| Number of CIL | ||||||
| Age ( | –0.05 | –0.01 (–0.04, 0.01) | 0.30 | |||
| Male gender ( | 0.19 | 1.31 (0.68, 1.94) | <0.001 | 0.14 | 0.98 (0.31, 1.66) | 0.01 |
| Chinese ethnicity ( | –0.04 | –1.13 (–3.68, 1.41) | 0.38 | |||
| Smoking ( | 0.15 | 1.19 (0.47, 1.91) | 0.001 | 0.08 | 0.62 (–0.16, 1.40) | 0.12 |
| Regular alcohol use ( | 0.06 | 0.64 (–0.43, 1.71) | 0.24 | |||
| Age of back pain onset ( | –0.08 | –0.02 (–0.04, 0.00) | 0.08 | –0.04 | –0.01 (–0.03, 0.01) | 0.44 |
| Duration of back pain ( | 0.04 | 0.01 (–0.02, 0.04) | 0.45 | |||
| Family history of SpA ( | –0.001 | –0.01 (–0.76, 0.74) | 0.98 | |||
| HLA-B27 positivity ( | 0.12 | 1.04 (0.20, 1.88) | 0.02 | 0.07 | 0.65 (–0.20, 1.50) | 0.13 |
| Radiographic axial SpA ( | 0.21 | 1.45 (0.82, 2.08) | <0.001 | 0.16 | 1.13 (0.47, 1.80) | <0.001 |
| Number of FCL | ||||||
| Age ( | 0.25 | 0.14 (0.09, 0.20) | <0.001 | 1.92 | 1.12 (–0.71, 2.96) | 0.23 |
| Male gender ( | 0.20 | 3.23 (1.73, 4.74) | <0.001 | 0.19 | 3.22 (1.66, 4.79) | <0.001 |
| Chinese ethnicity ( | 0.01 | 0.42 (–5.68, 6.52) | 0.89 | |||
| Smoking ( | 0.88 | 2.10 (0.36, 3.84) | 0.02 | 0.02 | 0.35 (–1.48, 2.19) | 0.71 |
| Regular alcohol use ( | 0.08 | 2.30 (–0.26, 4.86) | 0.08 | 0.01 | 0.20 (–2.45, 2.85) | 0.88 |
| Age of back pain onset ( | 0.03 | 0.07 (0.01, 0.12) | 0.02 | –1.60 | –0.96 (–2.80, 0.87) | 0.30 |
| Duration of back pain ( | 0.17 | 0.12 (0.05, 0.18) | <0.001 | –1.32 | –0.96 (–2.79, 0.87) | 0.31 |
| Family history of SpA ( | –0.06 | –1.12 (–2.90, 0.67) | 0.22 | |||
| HLA-B27 positivity ( | 0.17 | 3.70 (1.69, 5.71) | <0.001 | 0.15 | 3.20 (1.23, 5.17) | <0.01 |
| Radiographic axial SpA ( | 0.20 | 3.30 (1.78, 4.81) | <0.001 | 0.14 | 2.29 (0.73, 3.85) | <0.01 |
B, standard coefficient; CI, confidence interval; CIL, corner inflammatory lesion; FCL, fatty corner lesion; HLA, human leucocyte antigen; n, number; SpA, spondyloarthritis.